OR WAIT null SECS
April 25, 2024
Article
A retrospective challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.
April 19, 2024
Podcast
In this episode, hosts break down the latest type 2 diabetes recommendations from the American College of Physicians and offer their perspective on second-line therapies in T2D.
The American College of Physicians released new recommendations for the management of type 2 diabetes with inadequate glycemic control using metformin or other first-line therapies.
During this Q&A interview, Crandall discussed the takeaways from her portion of an ACP conference presentation on current clinical guidelines in type 2 diabetes.
April 18, 2024
Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.
April 17, 2024
In this episode, hosts discuss the STEP HFpEF DM trial and the need for fair allocation of incretin-based therapies with ongoing shortages and overwhelming demand.
April 13, 2024
The proposed insulin glargine biosimilar (Basalin) showed comparable immunogenicity, efficacy, and safety to the originator (Lantus) in a phase 3 equivalence trial.
April 04, 2024
Prices of nearly all insulins, SGLT2 inhibitors, and GLP1As could be reduced if robust generic or biosimilar manufacture were enabled.
April 03, 2024
In this endocrinology month in review for March 2024, we recap the most popular FDA news and pipeline updates as well as recognizing the 2-year anniversary of Diabetes Dialogue.
March 30, 2024
In this episode, hosts discuss GLP-1 RA use and CGM technology, updates in once-weekly insulins, the concept of continuous ketone monitoring, and practical application of artificial intelligence into care.
